Antibody for resisting dengue virus or NS1 protein thereof and application thereof

Abstract

The invention discloses an antibody for resisting dengue virus or NS1 protein thereof and application of the antibody, and relates to the field of antibodies. The antibody for resisting the dengue virus or the NS1 protein of the dengue virus comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of the dengue virus or the NS1 protein of the dengue virus, and has good affinity or activity.

Description

Technical Field

[0001] The present invention relates to the technical field of antibodies, and in particular to an antibody against dengue virus or its NS1 protein and an application thereof. Background Art

[0002] Dengue fever (DF) is an acute mosquito-borne infectious disease caused by four serotypes of viruses (DENV-1, DENV-2, DENV-3, and DENV-4), which are mainly transmitted by Aedes aegypti and Aedes albopictus. DF is the most widely distributed, most common, and most harmful insect-borne viral disease, and is widely prevalent in more than 100 countries and regions in tropical and subtropical Africa, the Americas, Southeast Asia, and the Western Pacific.

[0003] Clinically, DF is a severe flu-like disease. The main symptoms are sudden onset, high fever, severe headache, pain behind the eye sockets, muscle and joint pain, which may be accompanied by rash, swollen lymphadenopathy and leukopenia. It can affect all people, but the symptoms may vary depending on the age of the patient. This type of disease is generally called classical dengue fever. This type spreads rapidly and can cause a large-scale epidemic. During the dengue epidemic period, the incidence rate of susceptible people is usually 40%-50%, and can be as high as 80%-90%, but the mortality rate is very low. Dengue hemorrhagic fever is characterized by high fever, bleeding, hepatomegaly, and circulatory failure in severe cases. It has a high mortality rate and is a more serious clinical type. The disease accompanied by shock syndrome is called dengue shock syndrome.

[0004] There is no specific treatment for dengue fever. Without appropriate treatment, the mortality rate of dengue hemorrhagic fever can exceed 20%. With effective supportive therapy, the mortality rate can be lower than 1%. Key points for diagnosis of dengue fever: 1) Epidemiological data, activities in the 15 days before onset, whether the patient has been to the epidemic area, and history of mosquito bites; 2) Clinical features, sudden onset, fever, "three pains and three reds", skin diagnosis; 3) Laboratory examination, decreased white blood cells and platelets; serum characteristic IgM positive; IgG in the recovery period increases 4 times compared with the acute period; virus or specific antigen is isolated.

[0005] At present, the detection methods for dengue virus include virus culture, serological detection, immunoassay, etc. Virus isolation takes a long time and cannot achieve the purpose of rapid diagnosis, while conventional serological diagnosis is interfered by the existence of extensive cross-reactions. Immunoassay methods are fast, simple, do not rely on important equipment, and can achieve on-site detection. They have become a hot topic in the current research of rapid diagnosis of infectious diseases. The principle of immunoassay is a detection method based on antigen-antibody reaction. NS1 protein is a glycoprotein in the non-structural protein of dengue virus. It is highly antigenic and does not induce ADE, so it is often used as a target for immunoassay.

[0006] Immunoassays require antibodies against dengue virus or its NS1 protein. Therefore, there is a strong demand in the art for antibodies against dengue virus or its NS1 protein with good performance. Summary of the invention

[0007] The present application provides an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, which provides an important source of raw materials for the detection of dengue virus or its NS1 protein and has good activity or affinity.

[0008] In order to achieve the above-mentioned object, according to one aspect of the present invention, an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein is provided, wherein the antibody or the antigen-binding fragment thereof comprises three complementary determining regions of a heavy chain variable region having an amino acid sequence of any one of SEQ ID NOs: 17, 18, 19, and 20 and three complementary determining regions of a light chain variable region having an amino acid sequence of any one of SEQ ID NOs: 21, 22, 23, and 24.

[0009] In order to achieve the above object, according to a second aspect of the present invention, an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein is provided, wherein the antibody or the antigen-binding fragment thereof comprises the following complementary determining regions:

[0010] HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1;

[0011] HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2;

[0012] HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 3 or 33;

[0013] LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO:4;

[0014] LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and

[0015] LCDR3 comprises or consists of the amino acid sequence shown in SEQ ID NO: 6 or 34.

[0016] In order to achieve the above-mentioned object, according to the third aspect of the present invention, there is provided an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 17, 18, 19, and 20; and the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 21, 22, 23, and 24.

[0017] In order to achieve the above-mentioned object, according to the fourth aspect of the present invention, there is provided an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is shown in any one of SEQ ID NOs: 25, 26, 27, and 28; and the amino acid sequence of the light chain is shown in any one of SEQ ID NOs: 29, 30, 31, and 32.

[0018] In order to achieve the above object, according to the fifth aspect of the present invention, an antibody conjugate is provided, wherein the antibody conjugate comprises the above antibody or antigen-binding fragment thereof.

[0019] In order to achieve the above object, according to the sixth aspect of the present invention, a reagent or a kit is provided, wherein the reagent or the kit comprises the above-mentioned antibody or antigen-binding fragment thereof or the above-mentioned antibody conjugate.

[0020] In order to achieve the above-mentioned object, according to the seventh aspect of the present invention, a method for detecting dengue virus or its NS1 protein is provided, comprising: a) contacting the above-mentioned antibody or its antigen-binding fragment, antibody conjugate, or reagent or kit with dengue virus or its NS1 protein in a sample to be detected to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the antigen in the test sample.

[0021] In order to achieve the above-mentioned object, according to the eighth aspect of the present invention, there is provided a use of the above-mentioned antibody or antigen-binding fragment thereof, antibody conjugate, reagent or kit in the preparation of a product for detecting dengue virus or its NS1 protein.

[0022] In order to achieve the above object, the present invention also provides a nucleic acid, a vector, a cell and a method for preparing the above antibody or its antigen-binding fragment. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0024] Figure 1 The results of reducing SDS-PAGE of Anti-DN 10H3 Rmb1 to Anti-DN 10H3 Rmb7 are shown. DETAILED DESCRIPTION

[0025] In the first aspect, an embodiment of the present invention provides an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, wherein the antibody or the antigen-binding fragment thereof comprises three complementary determining regions having a heavy chain variable region of any one of the amino acid sequences SEQ ID NOs: 17, 18, 19, and 20 and three complementary determining regions having a light chain variable region of any one of the amino acid sequences SEQ ID NOs: 21, 22, 23, and 24.

[0026] It should be noted that HCDR1, HCDR2 and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2 and HCDR3 of the same heavy chain variable region defined in the antibody or antigen-binding fragment thereof described in the first aspect, and LCDR1, LCDR2 and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2 and LCDR3 of the same light chain variable region defined in the antibody or antigen-binding fragment thereof described in the first aspect.

[0027] For example, the HCDR1, HCDR2, and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, and HCDR3 of the heavy chain variable region shown in SEQ ID NO: 17; the LCDR1, LCDR2, and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, and LCDR3 of the light chain variable region shown in SEQ ID NO: 21.

[0028] In the present invention, the term "antibody" is used in the broadest sense and may include full-length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies, so long as they exhibit the desired biological activity.

[0029] In the present invention, the term "complementarity determining region", "CDR" or "CDRs" refers to the highly variable region of the heavy and light chains of immunoglobulins, and refers to the region containing one or more or even all of the major amino acid residues that play a role in the binding of an antibody or antigen-binding fragment to its recognized antigen or epitope. In a specific embodiment of the present invention, CDRs refers to the highly variable region of the heavy and light chains of the antibody.

[0030] In the present invention, the heavy chain complementarity determining region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determining region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.

[0031] The definition methods of CDR are well known in the art, and the CDR definition methods include: Kabat definition, Chothia definition, IMGT definition, Contact definition and AbM definition. As described herein, "Kabat definition" refers to the definition system described in Kabat et al., US Pept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). "Chothia definition" refers to Chothia et al., J Mol Biol 196: 901-917 (1987). There are other CDR definition methods that may not strictly follow one of the above schemes, but will still overlap with at least a portion of the CDR region defined by Kabat, although they may be shortened or extended based on predictions or experimental results of specific residues or residue groups. Exemplary defined CDRs are listed in Table 1 below, and the definitions in different documents are slightly different. Given the variable region amino acid sequence of an antibody, a person skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that CDRs defined by other methods not limited to Table 1 also belong to the scope of protection of the present disclosure.

[0032] Table 1: CDR Definition 1

[0033]

[0034]

[0035] 1 The numbering of all CDR definitions in Table 1 is based on the Kabat numbering system (see below), with the amino acid numbering on the heavy chain represented by "H+number" and the amino acid numbering on the light chain represented by "L+number". One of ordinary skill in the art can unambiguously map the Kabat numbering system to any variable region sequence without relying on any experimental data other than the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., U.S. Patent. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0036] 2 "AbM" as used in Table 1 with a lowercase "b" refers to CDRs defined by Oxford Molecular's "AbM" antibody modeling software.

[0037] 3If both H35A and H35B are absent, CDR-H1 ends at position 35; if only H35A is present, CDR-H1 ends at position 35A; if both H35A and H35B are present, CDR-H1 ends at position 35B.

[0038] 4 If both H35A and H35B are absent, CDR-H1 ends at position 32; if only H35A is present, CDR-H1 ends at position 33; if both H35A and H35B are present, CDR-H1 ends at position 34.

[0039] 5 If both H35A and H35B are absent, CDR-H1 ends at position 33; if only H35A is present, CDR-H1 ends at position 34; if both H35A and H35B are present, CDR-H1 ends at position 35.

[0040] According to an embodiment of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one system or a combination of multiple systems of Kabat, Chothia, IMGT, AbM or Contact.

[0041] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Kabat system.

[0042] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Chothia system.

[0043] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the IMGT system.

[0044] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the AbM system.

[0045] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a Contact system.

[0046] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM or Contact systems.

[0047] According to an embodiment of the present invention, the Kabat numbering positions corresponding to the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 defined by the Kabat, Chothia, AbM or IMGT systems are as follows:

[0048]

[0049]

[0050] In a second aspect, an embodiment of the present invention provides an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, wherein the antibody or the antigen-binding fragment thereof comprises the following complementary determining regions:

[0051] HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1;

[0052] HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2;

[0053] HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 3 or 33;

[0054] LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO:4;

[0055] LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and

[0056] LCDR3 comprises or consists of the amino acid sequence shown in SEQ ID NO: 6 or 34.

[0057] According to an embodiment of the present invention, the HCDRs and LCDRs are defined by the Kabat system.

[0058] In the present invention, the "framework region" or "FR" region includes the heavy chain framework region and the light chain framework region, and refers to the region other than the CDR in the heavy chain variable region and the light chain variable region of the antibody; wherein the heavy chain framework region can be further subdivided into adjacent regions separated by CDR, including HFR1, HFR2, HFR3 and HFR4 framework regions; the light chain framework region can be further subdivided into adjacent regions separated by CDR, including LFR1, LFR2, LFR3 and LFR4 framework regions.

[0059] In the present invention, the heavy chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0060] In an optional embodiment, the antibody or antigen-binding fragment thereof of the first aspect or the second aspect further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4;

[0061] The HFR1 comprises / is SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto;

[0062] The HFR2 comprises / is SEQ ID NO:8 or an amino acid sequence having at least 80% identity thereto;

[0063] The HFR3 comprises / is SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto;

[0064] The HFR4 comprises / is SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto;

[0065] The LFR1 comprises / is SEQ ID NO:11 or an amino acid sequence having at least 80% identity thereto;

[0066] The LFR2 comprises / is SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto;

[0067] The LFR3 comprises / is SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto;

[0068] The LFR4 comprises / is SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto.

[0069] It should be noted that, in other embodiments, the amino acid sequences of the framework regions of the antibodies or antigen-binding fragments thereof provided by the present invention against dengue virus or its NS1 protein may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the above-mentioned corresponding framework regions (SEQ ID NO: 7, 8, 9, 10, 11, 12, 13 or 14).

[0070] In an optional embodiment, the HFR3 comprises / is an amino acid sequence as shown in SEQ ID NO:35;

[0071] In an optional embodiment, the LFR1 comprises / is an amino acid sequence as shown in SEQ ID NO:36;

[0072] In an optional embodiment, the LFR4 comprises / is an amino acid sequence as shown in SEQ ID NO:37.

[0073] In a third aspect, an embodiment of the present invention provides an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 17, 18, 19, and 20, and the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 21, 22, 23, and 24.

[0074] In an optional embodiment, the heavy chain variable region and the light chain variable region described in the first aspect or the third aspect are selected from any combination of the following:

[0075] combination Heavy chain variable region Light chain variable region 1 SEQ ID NO:17 SEQ ID NO:21 2 SEQ ID NO:18 SEQ ID NO:21 3 SEQ ID NO:17 SEQ ID NO:22 4 SEQ ID NO:17 SEQ ID NO:23 5 SEQ ID NO:17 SEQ ID NO:24 6 SEQ ID NO:19 SEQ ID NO:23 7 SEQ ID NO:20 SEQ ID NO:21 .

[0076] In an optional embodiment, the antibody or antigen-binding fragment thereof of the first aspect, the second aspect or the third aspect further comprises a constant region.

[0077] In an alternative embodiment, the constant region includes a heavy chain constant region and / or a light chain constant region.

[0078] In an optional embodiment, the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG, IgA, IgM, IgE, and IgD, or a combination of multiple constant region segments.

[0079] In an alternative embodiment, the heavy chain constant region includes CH1 of IgG, a hinge region of IgG, CH2 of IgM, CH3 of IgM and / or CH4 of IgM.

[0080] In an alternative embodiment, the IgG is selected from IgG1, IgG2, IgG3 or IgG4.

[0081] In an alternative embodiment, the light chain constant region is selected from a kappa-type or a lambda-type light chain constant region.

[0082] In an alternative embodiment, the constant region is derived from a species of cow, horse, dairy cow, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock or human.

[0083] In an alternative embodiment, the species origin of the constant region is mouse.

[0084] In an optional embodiment, the heavy chain constant region sequence (CH) is as shown in SEQ ID NO:15, and the light chain constant region (CL) sequence is as shown in SEQ ID NO:16.

[0085] It should be noted that, in other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the above-mentioned constant region (SEQ ID NO: 15 or 16).

[0086] In an optional embodiment, the antigen-binding fragment is selected from any one of F(ab)2, F(ab')2, Fab', Fab, Fv and scFv of the antibody.

[0087] The antigen-binding fragments of the above antibodies usually have the same binding specificity as the antibodies from which they are derived. It is easy for those skilled in the art to understand based on the contents described in the present invention that the antigen-binding fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and / or by chemical reduction to split disulfide bonds. Based on the structure of the complete antibody disclosed in the present invention, those skilled in the art can easily obtain the above antigen-binding fragments.

[0088] The antigen-binding fragments of the above antibodies can also be synthesized by recombinant genetic techniques also known to those skilled in the art or by, for example, an automatic peptide synthesizer, such as those sold by Applied BioSystems and the like.

[0089] In a fourth aspect, the present invention provides an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is shown in any one of SEQ ID NOs: 25, 26, 27, and 28, and the amino acid sequence of the light chain is shown in any one of SEQ ID NOs: 29, 30, 31, and 32.

[0090] In an optional embodiment, the antibody or antigen-binding fragment thereof described in the first aspect, the second aspect, the third aspect or the fourth aspect comprises any combination of the following heavy chains and light chains:

[0091] combination Heavy chain Light chain 1 SEQ ID NO:25 SEQ ID NO:29 2 SEQ ID NO:26 SEQ ID NO:29 3 SEQ ID NO:25 SEQ ID NO:30 4 SEQ ID NO:25 SEQ ID NO:31 5 SEQ ID NO:25 SEQ ID NO:32 6 SEQ ID NO:27 SEQ ID NO:31 7 SEQ ID NO:28 SEQ ID NO:29 .

[0092] In a fifth aspect, the present invention provides an antibody conjugate, wherein the antibody conjugate comprises the above-mentioned antibody or antigen-binding fragment thereof.

[0093] In an optional embodiment, the above-mentioned antibody conjugate further comprises biotin or a biotin derivative conjugated to the antibody or antigen-binding fragment thereof.

[0094] In an optional embodiment, the antibody conjugate further comprises a label coupled to the antibody or antigen-binding fragment thereof.

[0095] In an optional embodiment, the above-mentioned marker refers to a class of substances with properties that can be directly observed by the naked eye or detected or detected by an instrument, such as luminescence, color development, radioactivity, etc., through which qualitative or quantitative detection of the corresponding target can be achieved.

[0096] In an alternative embodiment, the label includes but is not limited to fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent agents and nanoparticle labels.

[0097] In actual use, those skilled in the art can select a suitable marker according to the detection conditions or actual needs. No matter which marker is used, it belongs to the protection scope of the present invention.

[0098] In an optional embodiment, the fluorescent dye is not limited to fluorescein dyes and their derivatives (for example, including but not limited to fluorescein isothiocyanate (FITC), hydroxyfluorescein (FAM), tetrachlorofluorescein (TET), etc. or their analogs), rhodamine dyes and their derivatives (for example, including but not limited to red rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc. or their analogs), Cy series dyes and their derivatives (for example, including but not limited to Cy2, Cy3, Cy3B, Cy3.5, Cy3.7, Cy3.8, Cy3.9, Cy3.10, Cy3.11, Cy3.12, Cy3.13, Cy3.14, Cy3.15, Cy3.16, Cy3.17, Cy3.18, Cy3.19, Cy3.20, Cy3.21, Cy3.22, Cy3.23, Cy3.24, Cy3.25, Cy3.26, Cy3.27, Cy3.28, Cy3.29, Cy3.30, Cy3.31, Cy3.32, Cy3.33, Cy3.34, Cy3.35, Cy3.36, Cy3.37, Cy3.38, Cy3.39, Cy3.40, Cy3.41, Cy3.42, Cy3.43, Cy3.44, Cy3.45, Cy3.46, Cy3.47, Cy3.48, Cy3.49, Cy3.50, Cy3.51, Cy3.52, Cy3.53, Cy3.54, Cy3.55, Cy3.56, Cy3.57, Cy3.58, Cy3.59, Cy3.59, Cy3.59, Cy3.59, Cy3.59, Cy3.5 y5, Cy5.5, Cy3, etc. or their analogs), Alexa series dyes and their derivatives (for example, including but not limited to AlexaFluor350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, etc. or their analogs) and protein dyes and their derivatives (for example, including but not limited to phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), pre-chlorophyll protein (preCP), etc.).

[0099] In alternative embodiments, the enzyme includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and 6-phosphoglucose deoxygenase.

[0100] In an optional embodiment, the radioactive isotopes include but are not limited to 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu and 18F.

[0101] In an optional embodiment, the chemiluminescent reagent includes but is not limited to luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridine ruthenium and its derivatives, acridinium esters and their derivatives, dioxetanes and their derivatives, lophanes and their derivatives, and peroxyoxalates and their derivatives.

[0102] In an optional embodiment, the nanoparticle markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

[0103] In alternative embodiments, the colloid includes, but is not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.

[0104] In an alternative embodiment, the colloidal metal includes, but is not limited to, colloidal gold, colloidal silver, and colloidal selenium.

[0105] In an optional embodiment, the colloidal metal is colloidal gold.

[0106] In an optional embodiment, the above-mentioned antibody conjugate further includes a solid phase carrier coupled to the antibody or antigen-binding fragment thereof.

[0107] In an optional embodiment, the solid phase carrier includes but is not limited to magnetic microspheres, plastic microspheres, plastic microparticles, microwell plates, glass, capillaries, nylon and nitrocellulose membranes.

[0108] In a sixth aspect, the present invention provides a reagent or a kit, wherein the reagent or the kit comprises the above-mentioned antibody or antigen-binding fragment thereof or the above-mentioned antibody conjugate.

[0109] As mentioned above, the antibodies or antigen-binding fragments thereof in some embodiments or examples of the present invention can effectively bind to dengue virus or its NS1 protein, and therefore, the reagent or kit comprising the dengue virus or its NS1 protein antibody or antigen-binding fragment can effectively detect the dengue virus or its NS1 protein qualitatively or quantitatively. The reagent or kit provided by the present invention can be used, for example, for detection involving the use of dengue virus or its NS1 protein and its antibody-specific binding properties in immunoblotting, immunoprecipitation, etc. As mentioned above, the antibodies or antigen-binding fragments thereof in some embodiments or examples of the present invention have higher binding activity or affinity with dengue virus or its NS1 protein, and therefore the reagent or kit comprising the antibodies or antigen-binding fragments thereof has higher detection sensitivity or specificity.

[0110] In a seventh aspect, the present invention provides a method for detecting dengue virus or its NS1 protein, comprising: a) contacting the above-mentioned antibody or its antigen-binding fragment, antibody conjugate, reagent or kit with dengue virus or its NS1 protein in a sample to be detected to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the antigen in the test sample;

[0111] In an alternative embodiment, the immune complex further comprises a second antibody that binds to the antibody or antigen-binding fragment thereof.

[0112] In an optional embodiment, the immune complex further comprises a second antibody, which binds to the dengue virus or its NS1 protein.

[0113] Eighth aspect, the present invention provides the use of the above-mentioned anti-dengue virus or its NS1 protein antibody or its antigen-binding fragment, antibody conjugate or the above-mentioned reagent or kit in the preparation of a product for detecting dengue virus or its NS1 protein.

[0114] In a ninth aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned antibody or antigen-binding fragment thereof.

[0115] In a tenth aspect, the present invention provides a vector containing the above-mentioned nucleic acid molecule.

[0116] In an eleventh aspect, the present invention provides a cell containing the above-mentioned vector.

[0117] In a twelfth aspect, the present invention provides a method for preparing an antibody or an antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising: culturing the cells as described above.

[0118] Based on the amino acid sequence of the anti-dengue virus or its NS1 protein antibody or its antigen-binding fragment disclosed in the present invention, it is easy for those skilled in the art to conceive of using genetic engineering technology or other technologies (chemical synthesis, recombinant expression) to prepare the anti-dengue virus or its NS1 protein antibody or its antigen-binding fragment, for example, separating and purifying the antibody or its antigen-binding fragment from the culture product of a recombinant cell capable of recombinantly expressing the antibody or its antigen-binding fragment as described in any of the above items, which is easy to achieve for those skilled in the art. Based on this, no matter what technology is used to prepare the anti-dengue virus or its NS1 protein antibody or its antigen-binding fragment of the present invention, it belongs to the protection scope of the present invention.

[0119] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0120] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used for the practice or testing of the preparations or unit doses herein, some methods and materials are now described. Unless otherwise stated, the techniques adopted or considered herein are standard methods. Materials, methods and examples are illustrative and non-restrictive only.

[0121] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc.); Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0122] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0123] Example 1 Preparation of Anti-DN 10H3 Monoclonal Antibody

[0124] In this example, restriction endonucleases and Prime Star DNA polymerase were purchased from Takara. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART TMThe RACE cDNA Amplification Kit was purchased from Takara. The pMD-18T vector was purchased from Takara. The plasmid extraction kit was purchased from Tiangen. Primer synthesis and gene sequencing were completed by Invitrogen. The hybridoma cell line secreting Anti-DN 10H3 monoclonal antibody was prepared in this laboratory and revived for future use.

[0125] (1) Antibody gene preparation

[0126] mRNA was extracted from the hybridoma cell line secreting Anti-DN 10H3 monoclonal antibody, and the DNA product was obtained by RT-PCR. The product was inserted into the pMD-18T vector after A addition reaction with rTaq DNA polymerase and transformed into DH5α competent cells. After the colonies grew, the Heavy Chain and Light Chain gene clones were taken respectively, and 4 clones each were sent to a gene sequencing company for sequencing.

[0127] (2) Sequence analysis of the variable region gene of Anti-DN 10H3 antibody

[0128] The gene sequences obtained by the above sequencing were placed in the kabat antibody database for analysis, and the VNTI11.5 software was used for analysis to determine that the genes amplified by the heavy chain and light chain primer pairs were correct. Among the gene fragments amplified by the Light Chain, the VL gene sequence was 318bp, preceded by a 57bp leader peptide sequence; among the gene fragments amplified by the Heavy Chain primer pair, the VH gene sequence was 351bp, belonging to the VH1 gene family, preceded by a 57bp leader peptide sequence.

[0129] (3) Construction of recombinant antibody expression plasmid

[0130] pcDNA TM 3.4 vector is a recombinant antibody eukaryotic expression vector constructed, which has introduced multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector; according to the sequencing results of the antibody variable region genes in the above pMD-18T, the VL and VH gene-specific primers of the antibody were designed, with HindIII, EcoRI restriction sites and protective bases at both ends, respectively, and the 0.70kb Light Chain gene fragment and the 1.38kb Heavy Chain gene fragment were amplified by the PCR amplification method.

[0131] The Heavy Chain and Light Chain gene fragments were double-digested with HindIII / EcoRI, and the 3.4A vector was double-digested with HindIII / EcoRI. After the fragments and vectors were purified and recovered, the Heavy Chain gene and the Light Chain gene were respectively connected to the 3.4A expression vector to obtain the recombinant expression plasmids of Heavy Chain and Light Chain, respectively.

[0132] 2. Recombinant Antibody Production

[0133] Resuscitate HEK293 cells in advance and subculture them to 200 ml system to make the cell density reach 3-5×10 6 cells / ml, the cell density reaches the selected antibody concentration and cells, and the cell viability is >95%; the cells are washed by centrifugation and re-dissolved with culture medium, and the cell density is adjusted to 2.9×10 6 cells / ml, wash the cells, and re-dissolve them with culture medium, and use it as a cell diluent. Prepare plasmid DNA and transfection reagent diluents with culture medium respectively. Add the transfection reagent diluent to the plasmid DNA diluent, mix well and let stand at room temperature for 15 minutes; slowly add the mixture to the cell diluent within 1 minute, mix well and take samples to count, record and observe the viability of the cells after transfection, and place them in a 35℃ constant temperature incubator for culture, with a speed of 120rmp and a CO2 content of 8%. Centrifuge and collect samples after 13 days. The centrifuged supernatant was affinity purified using a proteinA affinity chromatography column. Take 6ug layer of purified antibodies for reducing SDS-PAGE, and the electrophoresis is shown in the figure. After reducing SDS-PAGE, two bands are shown, one Mr is 50KD (heavy chain) and the other Mr is 28KD (light chain).

[0134] The obtained antibody was named Anti-DN 10H3Rmb1. Anti-DN 10H3Rmb1 was mutated to obtain a mutant antibody. The sequences of the heavy chain (H) and light chain (L) of the above antibody are shown in the following table:

[0135] Table 2 Antibody sequences

[0136] Antibody Name Heavy chain Light chain Anti-DN 10H3Rmb1 SEQ ID NO:25 SEQ ID NO:29 Anti-DN 10H3Rmb2 SEQ ID NO:26 SEQ ID NO:29 Anti-DN 10H3Rmb3 SEQ ID NO:25 SEQ ID NO:30 Anti-DN 10H3Rmb4 SEQ ID NO:25 SEQ ID NO:31 Anti-DN 10H3Rmb5 SEQ ID NO:25 SEQ ID NO:32 Anti-DN 10H3Rmb6 SEQ ID NO:27 SEQ ID NO:31 Anti-DN 10H3Rmb7 SEQ ID NO:28 SEQ ID NO:29

[0137] Example 2 Performance testing of antibodies

[0138] 1. Activity identification

[0139] Coating solution (main component NaHCO3) diluted goat anti-mouse IgG 1ug / ml for microplate coating, 100uL per well, 4℃ overnight; the next day, wash twice with washing solution (main component Na2HPO4+Nacl), pat dry; add blocking solution (20% BSA+80% PBS), 120uL per well, 37℃, 1h, pat dry; add diluted purified antibody and control antibody, 100uL / well, 37℃, 60min; shake off the liquid in the plate, pat dry, add 20% mouse negative blood for blocking, 120ul per well, 37℃, 1h; shake off the liquid in the plate, pat dry , add diluted dengue NS1 antigen (from Feipeng Biotechnology), 100uL per well, 37℃, 40min; wash 5 times with detergent and pat dry; add HRP-labeled anti-dengue NS1 antibody (from Feipeng Biotechnology, which can be paired with purified antibody), 100uL per well, 37℃, 30min; add colorimetric solution A (50uL / well), add colorimetric solution B (50uL / well), 10min; add stop solution, 50uL / well; read OD value at 450nm (reference 630nm) on the microplate reader.

[0140] Note: Solution A (main ingredients: citric acid + sodium acetate + acetanilide + urea peroxide); Solution B (main ingredients: citric acid + EDTA·2Na + TMB + concentrated HCL); Stop solution (EDTA·2Na + concentrated H2SO4)

[0141] Table 3 Activity data

[0142] Concentration (ng / ml) 125.00 62.50 31.25 15.63 7.81 0.00 Comparison 1.202 0.658 0.371 0.197 0.076 0.024 Anti-DN 10H3Rmb1 1.702 1.168 0.703 0.468 0.203 0.036 Anti-DN 10H3Rmb2 1.753 1.084 0.661 0.479 0.199 0.037 Anti-DN 10H3Rmb3 1.868 1.203 0.828 0.503 0.316 0.034 Anti-DN 10H3Rmb4 1.963 1.782 0.996 0.723 0.487 0.034 Anti-DN 10H3Rmb5 2.064 1.786 1.162 0.756 0.455 0.037 Anti-DN 10H3Rmb6 1.921 1.343 0.613 0.324 0.207 0.022 Anti-DN 10H3Rmb7 2.033 1.504 0.898 0.465 0.196 0.053

[0143] 2. Application of antibodies in colloidal gold detection

[0144] 2.1 Preparation of colloidal gold test paper

[0145] 2.1.1 Preparation of nitrocellulose membrane

[0146] Preparation of nitrocellulose membrane: dilute anti-dengue NS1 protein antibody Anti-DN (purchased from Feipeng Bio) to 1-5 mg / mL with coating buffer, adjust the machine, draw a line as T, which is the detection line, and T line is close to the end of the gold standard pad; dilute goat anti-mouse IgG antibody to 1-5 mg / mL with coating buffer, adjust the machine, draw a line as C, which is the control line, and C line is close to the absorption pad. The distance between the two lines is 5-8 mm, even. Dry at 37℃, package and set aside.

[0147] 2.1.2 Preparation of colloidal gold and gold-labeled monoclonal antibodies

[0148] Dilute 1% chloroauric acid to 0.01% with double distilled deionized water, boil on an electric stove, add 2mL 1% trisodium citrate for every 100mL 0.01% chloroauric acid, continue boiling until the liquid turns bright red, then stop heating, and make up for the water loss after cooling to room temperature. The appearance of the prepared colloidal gold should be pure, transparent, and free of precipitation and floating matter.

[0149] Adjust the pH value of colloidal gold to 8.2 with 0.1M potassium carbonate, add the above antibodies Anti-DN 10H3Rmb1 to Anti-DN 10H3Rmb7 and control antibody respectively, mix with magnetic stirrer for 30 minutes, add BSA to a final concentration of 1% under stirring and let stand for 1 hour. Centrifuge at 13000rpm and 4℃ for 30 minutes, discard the supernatant, wash the precipitate twice with labeling washing solution, resuspend the precipitate with labeling washing solution of one tenth of the initial colloidal gold volume, and place the prepared colloidal gold labeled antibodies Anti-DN 10H3Rmb1 to Anti-DN 10H3Rmb7 at 4℃ for use.

[0150] 2.1.3 Preparation of gold label pad

[0151] Soak the gold-labeled pad in the blocking solution for 30 minutes and dry it at 37°C. Then spread the prepared gold-labeled antibody evenly on the gold-labeled pad, with 20 square centimeters per milliliter of solution, freeze-dry, package, and place at 4°C for later use.

[0152] 2.1.4 Assembly of test strips

[0153] The absorption pad (purchased from Millipore), nitrocellulose membrane, gold label pad and sample pad were placed on a non-absorbent support sheet and cut into 3 mm wide strips. Ten strips were packed into one package, desiccant was added, and vacuum packaged to obtain the test paper.

[0154] 2.2 Application of antibodies in colloidal gold detection

[0155] The assembled test strips are used to detect whether the material under test contains the dengue virus NS1 protein, thereby determining the effectiveness of antibodies Anti-DN 10H3Rmb1 to Anti-DN 10H3Rmb7 in detecting the dengue virus NS1 protein.

[0156] The double antibody sandwich method is used to detect whether the material under test contains dengue virus NS1 protein. During the detection, the dengue virus NS1 protein first combines with the colloidal gold-labeled antibody to form a dengue virus NS1 protein-colloidal gold-labeled antibody complex. Due to the capillary action, the dengue NS1 protein-colloidal gold-labeled antibody complex moves forward along the nitrocellulose membrane. When it reaches the detection line, the dengue virus NS1 protein-colloidal gold-labeled antibody complex will combine with the anti-dengue virus NS1 protein antibody Anti-DN prepared in step 3.1.1 of the above embodiment to form an Anti-DN-dengue virus NS1 protein-colloidal gold-labeled antibody complex, thereby enriching on the detection line to form a red precipitation line. The dengue virus NS1 protein-colloidal gold-labeled antibody complex that is not combined with the dengue virus NS1 protein antibody on the detection line passes through the detection line, is captured by the sheep anti-mouse IgG antibody, and is enriched on the quality control line to form a red precipitation line. When the detection line and the quality control line have red precipitation lines at the same time, it is judged as a positive result. If the sample does not contain dengue virus NS1 protein, when the colloidal gold-labeled antibody that is not bound to the dengue virus NS1 protein reaches the detection line, no complex of Anti-DN-dengue virus NS1 protein-colloidal gold-labeled antibody will be formed. The colloidal gold-labeled antibody complex that is not bound to the dengue virus NS1 protein passes through the detection line and is only enriched on the quality control line to form a red precipitation line, which is then judged as a negative result.

[0157] Note: The gold label color is composed of C plus a number. The smaller the number after C, the stronger the color and the higher the activity; the higher the number after C, the weaker the color and the lower the activity; the number followed by "+" means slightly stronger by 0.5C, the number followed by "-" means slightly weaker by 0.5C, and "B" represents negative. Note: DENV-2 / 3 / 4: positive quality control product Random serum: negative quality control product

[0158] Table 4 Performance evaluation data

[0159] Sample name DENV-2 DENV-3 DENV-4 Random serum Comparison C3 C4 C6+ B Anti-DN 10H3Rmb1 C2 C4+ C6+ B Anti-DN 10H3Rmb2 C2 C4 C6 B Anti-DN 10H3Rmb3 C2 C4+ C6+ B Anti-DN 10H3Rmb4 C2 C4 C5+ B Anti-DN 10H3Rmb5 C2+ C4+ C5+ B Anti-DN 10H3Rmb6 C2+ C4 C5+ B Anti-DN 10H3Rmb7 C2 C4+ C5 B

[0160] 3. Stability assessment

[0161] The above antibodies were placed at 4°C (refrigerator), -80°C (refrigerator), and 37°C (constant incubator) for 21 days, and samples were taken for 7 days, 14 days, and 21 days for status observation, and the activity of the 21-day samples was tested. The results showed that no obvious protein state changes were observed in the antibodies placed for 21 days under the three test conditions, and the activity did not show a downward trend with the increase of the test temperature, indicating that the above antibodies are stable. Table 5 below shows the OD results of the enzyme immunoassay activity test of the antibody Anti-DN 10H3 Rmb4 for 21 days.

[0162] Table 5 Stability data

[0163] Sample concentration (ng / ml) 62.50 31.25 0.00 4℃, 21-day samples 1.735 1.165 0.028 -80℃, 21 days sample 1.776 1.174 0.029 37℃, 21 days sample 1.709 1.188 0.024

[0164] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

[0165] Some of the amino acid sequences involved in this application are shown in Table 6:

[0166]

[0167]

[0168]

Claims

1. An antibody or antigen-binding fragment thereof against dengue virus or its NS1 protein, characterized in that The antibody or antigen-binding fragment thereof comprises three complementarity determining regions of a heavy chain variable region having an amino acid sequence of any one of SEQ ID NOs: 17, 18, 19, and 20 and three complementarity determining regions of a light chain variable region having an amino acid sequence of any one of SEQ ID NOs: 21, 22, 23, and 24.

2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The complementarity determining regions of the variable regions are defined by any one of the Kabat, Chothia, IMGT, AbM or Contact systems or a combination of multiple systems.

3. An antibody or antigen-binding fragment thereof against dengue virus or its NS1 protein, characterized in that: The antibody or antigen-binding fragment thereof comprises the following complementarity determining regions: HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1; HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2; HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 3 or 33; LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO:4; LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and LCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 6 or 34; Optionally, the antibody or antigen-binding fragment thereof further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4; The HFR1 comprises SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto; The HFR2 comprises SEQ ID NO: 8 or an amino acid sequence having at least 80% identity thereto; The HFR3 comprises SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto; The HFR4 comprises SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto; The LFR1 comprises SEQ ID NO: 11 or an amino acid sequence having at least 80% identity thereto; The LFR2 comprises SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto; The LFR3 comprises SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto; The LFR4 comprises SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto.

4. An antibody or antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising a heavy chain variable region and / or a light chain variable region, characterized in that: The amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 17, 18, 19, and 20; the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 21, 22, 23, and 24; Optionally, the combination of the heavy chain variable region and the light chain variable region is selected from any one of the following combinations: ； Optionally, the antibody or antigen-binding fragment thereof further comprises a constant region; Optionally, the constant region includes a heavy chain constant region and / or a light chain constant region; Optionally, the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG, IgA, IgM, IgE, and IgD, or a combination of multiple constant region segments; Optionally, the heavy chain constant region includes CH1 of IgG, hinge region of IgG, CH2 of IgM, CH3 of IgM and / or CH4 of IgM; Optionally, the species of the constant region is cattle, horse, pig, sheep, goat, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose or human; Optionally, the species origin of the constant region is mouse; Optionally, the heavy chain constant region sequence is as shown in SEQ ID NO: 15 or has at least 80% identity thereto; Optionally, the light chain constant region sequence is as shown in SEQ ID NO: 16 or has at least 80% identity thereto; Optionally, the antigen-binding fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody.

5. An antibody or antigen-binding fragment thereof against dengue virus or its NS1 protein, comprising a heavy chain and / or a light chain, characterized in that: The amino acid sequence of the heavy chain is shown in any one of SEQ ID NOs: 25, 26, 27, and 28; the amino acid sequence of the light chain is shown in any one of SEQ ID NOs: 29, 30, 31, and 32.

6. An antibody conjugate, characterized in that: The antibody conjugate comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; Optionally, the antibody conjugate further comprises biotin or a biotin derivative conjugated to the antibody or antigen-binding fragment thereof; Optionally, the antibody conjugate further comprises a label coupled to the antibody or antigen-binding fragment thereof; Optionally, the label is selected from fluorescent dyes, enzymes, radioisotopes, chemiluminescent agents and nanoparticle labels; Optionally, the antibody conjugate further comprises a solid phase carrier coupled to the antibody or antigen-binding fragment thereof.

7. A reagent or a kit, characterized in that: The reagent or kit comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 or the antibody conjugate according to claim 6.

8. A method for detecting dengue virus or its NS1 protein, characterized in that: include: a) contacting the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, the antibody conjugate according to claim 6, or the reagent or kit according to claim 7 with dengue virus or its NS1 protein in a sample to be detected to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and b) detecting the presence of the immune complex, the presence of the complex indicating the presence of the antigen in the test sample; Optionally, the immune complex further comprises a second antibody, which binds to the antibody or antigen-binding fragment thereof; Optionally, the immune complex further comprises a second antibody, which binds to the dengue virus or its NS1 protein.

9. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, the antibody conjugate according to claim 6, or the reagent or kit according to claim 7 in the preparation of a product for detecting dengue virus or its NS1 protein.

10. A nucleic acid, a vector, a cell, or a method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the nucleic acid encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; the vector contains a nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; the cell contains the above-mentioned nucleic acid or vector; the method contains the above-mentioned cell.

Images